Vitiligo

Vitiligo patients exhibit a distinct temperament profile and tend to be less resilient toward psychological stressors. Vitiligo is a skin disorder associated with psychiatric comorbidities, including suicidality, low self-esteem, and depression. Vitiligo patients have a characteristic premorbid temperament profile associated with affective traits, including high anxiety and low hyperthymic temperament traits. The findings of this...

Individuals diagnosed with vitiligo have significantly greater levels of anti-thyroid peroxidase and anti-thyroglobulin antibodies, which are the markers of autoimmune thyroid diseases. Vitiligo is an acquired skin disorder characterized by progressive melanocyte loss. Vitiligo is associated with autoimmune disorders, the most prevalent being autoimmune conditions of the thyroid. Vitiligo patients have significantly higher levels of...

Natural compounds, including antioxidants, contribute to the improvement of both vitiligo and associated mental health disorders, leading to a limited need for therapies and a better quality of life. Vitiligo is described as an autoimmune dermatosis and is often associated with mental health disorders. However, the cause–effect relationship between the two is yet to be...

Vitiligo increases the risk for thyroid disease, especially in women. These autoimmune disorders should be integrated into the decision-making process around screening for diseases. Autoimmune thyroid disease is more common in people with vitiligo. Women are more likely to have both vitiligo and a thyroid disorder. Vitiligo should be considered a risk factor for other...

In vitiligo, regulatory T cells suppress autoimmune responses that worsen disease, but only if they contain the chemokine receptor CCR6, according to a recent study. Effector T cells destroy melanocytes, leading to vitiligo lesions. Regulatory T cells suppress effector T cell activity and improve disease. The chemokine CCR6 is necessary to bring regulatory T cells...

Treatments for vitiligo are most effective when started early, with those experiencing later onset and less affected skin surface area receiving treatment sooner. Several demographic and disease-related factors are associated with treatment delays in vitiligo patients.  Treatments for vitiligo are most effective when delivered early in the disease course. People with vitiligo onset after age...

Vitiligo lesions can be treated with antibodies, but off-target effects may be harmful. Injection with a bispecific antibody returns pigmentation only to the area of injection and limits systemic side effects. Vitiligo, an autoimmune condition, can be treated with immunosuppressant drugs. Local injection of skin lesions is preferable to systemic treatment because off-target side effects...

Stable vitiligo skin lesions have a distinct cellular makeup compared to active vitiligo melanocytes due to their unique genetic signatures and metabolic profiles, causing proinflammatory responses and a “stressed” cellular state. Stable vitiligo lesions have cellular profiles that are distinct from those of active vitiligo melanocytes. Keratinocytes in depigmented lesions have distinct genetic signatures and...

A retrospective study found that Black patients with vitiligo have high rates of comorbid autoimmune diseases. Vitiligo is a condition that causes loss of skin color in patches that can get larger over time. A 2020 retrospective study examined the diseases associated with vitiligo in the New York City population.  The researchers evaluated the data...